<DOC>
	<DOC>NCT02768662</DOC>
	<brief_summary>This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study 104-201403 (1-Year, Phase 2, Safety Study of OTO-104) or 104-201508 (Phase 3 Study of OTO-104) in order to be eligible for this open-label extension study.</brief_summary>
	<brief_title>A 6-Month Extension Study of OTO-104 in Meniere's Disease</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject has completed the Phase 2 OTO104 1Year Safety Study (104201403) or Phase 3 (104201508) clinical study. Subject has a diagnosis of definite unilateral Meniere's disease by 1995 AAOHNS criteria Exclusion Criteria includes, but is not limited to: Subject is pregnant or lactating. Subject has a history of immunodeficiency disease. Subject has experienced an adverse reaction to intratympanic injection of steroids.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>